Nanosonics has a long runway for growth

It’s a testing time for investors, with so many hitherto great businesses on their knees, and others looking well over-priced. But it’s still possible to identify structural winners with a long growth runway at reasonable prices. I think one of these could be Sydney-based medical device innovator, Nanosonics (ASX:NAN).

Confronted with a highly uncertain global macro backdrop and a ‘lower for longer’ interest rate outlook, we have strategically positioned our portfolio towards the clear beneficiaries of positive structural trends which are accelerating in a COVID-19 impacted world, such as cloud, e-commerce, digital payments and medical technologies, and away from the most heavily disrupted sectors like old-world media, retail and REITS. In control of their own destiny, we expect these resilient and innovative structural winners to continue exploiting their competitive advantage, taking share from low-tech incumbents, and growing independently of the economic cycle.

Exclusive Content

Exclusive Content

This is exclusive content to subscribers on View the full article via your subscription or sign up for access.



View all funds